Use of berbamine dihydrochloride in preparation of Ebola virus inhibitor
US12329754B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 10, 2023 |
| Grant date | Jun 17, 2025 |
| Priority date | — |
| Expiry date | Feb 22, 2044 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides use of berbamine dihydrochloride in preparation of an Ebola virus inhibitor. In the present invention, the primed glycoprotein of the Ebola virus (EBOV-GPcl) is taken as a target site, and an antiviral active compound with the capability of binding to the EBOV-GPcl, i.e., berbamine dihydrochloride, is obtained through structure-based virtual screening. Berbamine dihydrochloride can specifically inhibit the entry of an Ebola recombinant virus by binding to the target protein EBOV-GPcl, thereby achieving the effect of anti-Ebola virus infection. The half-maximum effect concentration (EC50) of berbamine dihydrochloride against EBOV is 0.49 μM, which indicates that berbamine dihydrochloride has a strong inhibition effect on EBOV.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.